Sumitomo Mitsui Trust Group Inc. Raises Position in Henry Schein, Inc. $HSIC

Sumitomo Mitsui Trust Group Inc. grew its position in Henry Schein, Inc. (NASDAQ:HSIC) by 24.8% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 6,272 shares of the company’s stock after acquiring an additional 1,247 shares during the period. Sumitomo Mitsui Trust Group Inc.’s holdings in Henry Schein were worth $458,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Steph & Co. purchased a new stake in Henry Schein during the second quarter worth about $44,000. CX Institutional boosted its holdings in Henry Schein by 107.3% during the second quarter. CX Institutional now owns 651 shares of the company’s stock worth $48,000 after buying an additional 337 shares in the last quarter. TD Private Client Wealth LLC boosted its holdings in Henry Schein by 103.0% during the second quarter. TD Private Client Wealth LLC now owns 668 shares of the company’s stock worth $49,000 after buying an additional 339 shares in the last quarter. Whittier Trust Co. boosted its holdings in Henry Schein by 714.3% during the first quarter. Whittier Trust Co. now owns 798 shares of the company’s stock worth $55,000 after buying an additional 700 shares in the last quarter. Finally, Quarry LP purchased a new stake in Henry Schein during the first quarter worth about $71,000. Hedge funds and other institutional investors own 96.62% of the company’s stock.

Henry Schein Stock Performance

NASDAQ:HSIC opened at $63.20 on Friday. The firm has a 50 day simple moving average of $66.19 and a 200-day simple moving average of $68.50. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.41 and a quick ratio of 0.78. The firm has a market cap of $7.66 billion, a PE ratio of 20.39, a P/E/G ratio of 2.06 and a beta of 0.81. Henry Schein, Inc. has a 1-year low of $60.56 and a 1-year high of $82.49.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $1.10 earnings per share for the quarter, missing analysts’ consensus estimates of $1.19 by ($0.09). The firm had revenue of $3.24 billion during the quarter, compared to analyst estimates of $3.22 billion. Henry Schein had a net margin of 3.05% and a return on equity of 14.36%. The business’s quarterly revenue was up 3.3% on a year-over-year basis. During the same period in the prior year, the firm earned $1.23 EPS. Henry Schein has set its FY 2025 guidance at 4.800-4.940 EPS. On average, equities analysts expect that Henry Schein, Inc. will post 4.74 EPS for the current year.

Analyst Ratings Changes

A number of analysts recently commented on HSIC shares. Stifel Nicolaus reissued a “hold” rating and set a $75.00 price objective (down previously from $80.00) on shares of Henry Schein in a report on Friday, July 25th. Weiss Ratings reissued a “hold (c-)” rating on shares of Henry Schein in a report on Friday. Baird R W downgraded shares of Henry Schein from a “strong-buy” rating to a “hold” rating in a report on Monday, July 14th. Evercore ISI upgraded shares of Henry Schein from an “in-line” rating to an “outperform” rating and set a $83.00 target price for the company in a research report on Tuesday, August 26th. Finally, UBS Group cut their target price on shares of Henry Schein from $75.00 to $70.00 and set a “neutral” rating for the company in a research report on Wednesday, August 6th. Five investment analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $76.67.

Henry Schein Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.